期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HPV L1壳蛋白检测在宫颈病变诊治中应用的进展 被引量：3

原文传递
导出
摘要 宫颈癌是女性最常见的恶性肿瘤之一,而高危型人乳头瘤病毒(human papillomavirus,HPV)的持续感染是导致宫颈癌的主要病因。HPV L1壳蛋白是人乳头瘤病毒的主要结构蛋白,是病毒感染细胞和细胞免疫反应攻击病毒的主要靶位。HPV L1壳蛋白与宫颈细胞学、组织病理学、患者年龄、人乳头瘤病毒负荷量也呈现一定的相关性。本文综述HPV L1壳蛋白对宫颈病变的预测作用。
作者 钱敏 尤志学
机构地区 南京医科大学第一临床医学院 南京医科大学第一附属医院妇科
出处 《江苏医药》 CAS CSCD 北大核心 2012年第13期1579-1582,共4页 Jiangsu Medical Journal
关键词 宫颈病变 HPV 壳蛋白 高危型人乳头瘤病毒 应用 诊治 检测 细胞免疫反应
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Doorbar J.Molecular biology of human papillomavirus infectionand cervical cancer[J].Clin Sci,2006,110(5):525-541.
  • 2Mougin C,Mo L,Dalstein V.Natural history of papilloma-virus infections[J].Rev Prat,2006,56(17):1883-1889.
  • 3Lukaszuk K,Liss J,Wozniak I,et al.Human papillomavirustype 16status in cervical carcinoma cell DNA assayed bymultiplex PCR[J].J Clin Microbiol,2003,41(2):608-612.
  • 4Balan R,GiuscS,Cruntu ID,et al.Immunochemicalassessment of p16and HPV L1capsid protein in cervicalsquamous intraepithelial lesions[J].Rev Med Chir Soc MedNat Iasi,2010,114(4):1118-1124.
  • 5Ungureanu C,Socolov D,Anton G,et al.Immunocytochemicalexpression of p16INK4aand HPV L1 capsid proteins aspredictive markers of the cervical lesions progression risk[J].Rom J Morphol Embryol,2010,51(3):497-503.
  • 6Hopman AH,Smedts F,Dignef W,et al.Transition of high-grade cervical intraepithelial neoplasia to micro-invasivecarcinoma is characterized by integration of HPV 16/18andnumerical chromosome abnormalities[J].J Pathol,2004,202(1):23-33.
  • 7冷若冰,唐良萏.HPV L1壳蛋白检测联合细胞学在宫颈病变筛查中的临床应用[J].中国现代医学杂志,2011,21(28):3506-3509. 被引量：14
  • 8Arbyn M,Sasieni P,Meijer CJ,et al.Chapter 9:Clinicalapplications of HPV testing:a summary of meta-analyses[J].Vaccine,2006,24(Suppl 3):78-89.
  • 9Stemberger-Papic S, Vrdoljak-Mozetic D, Ostojic DV, et al. Evaluation of the HPV L1 capsid protein in prognosis of mild and moderate dysplasia of the cervix uteri[J]. Coll Antropol, 2010,34(2) :419-423.
  • 10Sarmadi S,Izadi-Mood N,Pourlashkari M,et al.HPV L1capsid protein expression in squamous intraepithelial lesionsof cervix uteri and its relevance to disease outcome[J].ArchGynecol Obstet,2012,285(3):779-784.

二级参考文献46

  • 1DHN D,TORKKO K C,SHROYER R. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma[J]. Cancer, 2007,111 ( 1 ) : 1-14.
  • 2DENNY L. The prevention of cervical cancer in developing countries [J]. BJOG,2005,112(9) : 1204-1212.
  • 3NAME J,KIM J W,KIM S W,et al. The expressions of the Rbpathway in cervical intraepitheial neoplasia: predictive and prognostic significance[J]. Gyneeol Oncol, 2007,104 (1) : 207- 211.
  • 4CANTOR S B, ATKINSON E N, CARDENAS-TURANZAS M, et al. Natural history of cervical intraepithelial neoplasia [J]. Acta Cytol,2005,49(6) :405-415.
  • 5MELSHEIMER P, KAUL S, DOBECK S, et al. Immunocytochemical detection of human papillomavirus high risk type L1 caspid protein in LISL and HISL as compared with detection of HPV L1 DNA [J]. Acta Cytol,2003,47(4) :124-128.
  • 6CORINCZ A T,CASTLE P E,SHEMAN M E,et al. Ki-67 predicts progression inearly CIN, Validation of a multirariate progression risk model [J]. Cell Oneol,2004,26(1/2) ;13-20.
  • 7SONG S H,PARK H M,EOM D W,et al. The expression of p16 and ki-67 in relation to high risk human papiloma viral load and residual disease after conization with positive mar gins [J]. Int J Gyneeol Cancer,2007,17(4):858- 867.
  • 8MCMURRY H R,NGUYEN D,WESTBROOK T E,et al. Biology of human papillomaviruses[J]. Int J Exp Path,2001,82 (3) :15-33.
  • 9RODEN R,WU T C. How will HPV caccines affect cervical cancer? [J]. Rev Cancer,2006,21(7) 1753-763.
  • 10YOSHIDA T,SANO T,KANUMA T,et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid based cytology samples from uterine cervical lesions [J]. Cancer,2008,114(2) :83- 88.

共引文献68

同被引文献51

  • 1吕卫国,谢幸.宫颈癌的筛查[J].中国实用妇科与产科杂志,2006,22(1):8-9. 被引量：95
  • 2钱德英,岑坚敏,王丁,曾仁海,林爱华,舒焰红,洪淡华,黄志宏.高危型人乳头状瘤病毒DNA检测与细胞学联合检查对子宫颈癌前病变筛查的研究[J].中华妇产科杂志,2006,41(1):34-37. 被引量：168
  • 3吕卫国,沈源明,叶枫,陈怀增,谢幸.阴道镜直视下活检诊断宫颈上皮内瘤变准确性的评价[J].中华医学杂志,2006,86(5):303-306. 被引量：107
  • 4卞美璐,陈庆云,张小燕,欧华,刘军.对宫颈细胞学诊断意义未明的不典型鳞状细胞患者的临床管理[J].中华医学杂志,2006,86(33):2339-2342. 被引量：8
  • 5Abularia O, Pezzullo JC, Sherer DM. Performance of ThinPrep liquid-based cervical cytology in comparison with conven- tionally prepared Papanicolaou smears: a quantitative survey [-J]. Gynecol Oncol,2003,90(1) : 137-144.
  • 6Obwegeser JH, Brack S. Does Liquid-based technology really improve detection ofcervical neoplasia[J]. Acta Cytol, 2001, 45(5) :709-714.
  • 7Wi'ight TC Jr, Massad LS, Dunton CJ, et al. 2006 Consensus guidelines for the management of women with abnormal cervical screening tests[J]. J Low Genit Tract Dis, 2007, 11 (4) : 201-222.
  • 8Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicalaou screening tests for cervical canccr[J]. N Engl J Med,2007,357(16) ; 1579-1588.
  • 9Zhao FH, Lin MJ, Chen F, at al. Performance of high-risk human papitlomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population based studies from China[J]. Lancet Oncal, 2011,12(1) : 11.
  • 10Wright TC Jr. Cervicalcancer screening in the 21st century： Is it time to retire the PAP smear[J]. Clin Obstet Gynecol, 2007,50 (2) ： 313-323.

引证文献3

二级引证文献9

江苏医药
2012年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部